Weekly Research Analysts’ Ratings Updates for Janux Therapeutics (JANX)

Several analysts have recently updated their ratings and price targets for Janux Therapeutics (NASDAQ: JANX):

• 11/22/2024 – Janux Therapeutics was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 11/22/2024 – Janux Therapeutics is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $79.00 price target on the stock.
• 11/14/2024 – Janux Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 11/7/2024 – Janux Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $100.00 price target on the stock.
• 11/7/2024 – Janux Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $63.00 price target on the stock.
• 10/24/2024 – Janux Therapeutics is now covered by analysts at UBS Group AG. They set a “buy” rating and a $69.00 price target on the stock.

Janux Therapeutics Stock Performance

NASDAQ:JANX traded down $0.85 during trading hours on Tuesday, hitting $47.97. The company’s stock had a trading volume of 247,563 shares, compared to its average volume of 709,487. Janux Therapeutics, Inc. has a 52-week low of $7.79 and a 52-week high of $65.60. The company has a market capitalization of $2.52 billion, a PE ratio of -41.00 and a beta of 3.52. The business’s 50-day moving average is $50.05 and its two-hundred day moving average is $45.83.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s revenue was down 82.6% on a year-over-year basis. As a group, analysts predict that Janux Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at $15,101,171.16. The trade was a 8.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Andrew Hollman Meyer sold 50,000 shares of Janux Therapeutics stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the transaction, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 420,610 shares of company stock valued at $19,288,666. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in JANX. Plato Investment Management Ltd grew its stake in shares of Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank grew its stake in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares in the last quarter. Summit Securities Group LLC bought a new position in Janux Therapeutics during the second quarter valued at about $29,000. Finally, Virtu Financial LLC boosted its stake in Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after buying an additional 2,419 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.